Navigation Links
Can cancer drugs combine forces?
Date:8/16/2007

Individuals with chronic myeloid leukemia (CML) are treated first with a drug known as imatinib (Gleevec), which targets the protein known to cause the cancer (BCR-ABL). If their disease returns, because BCR-ABL mutants emerge that are resistant to the effects of imatinib, individuals are treated with a drug known as dasatinib (SPRYCEL), which targets BCR-ABL in a different way. However, patients that relapse after treatment with dasatinib, because BCR-ABL mutants emerge that are resistant to the effects of this drug, are now beginning to be seen in the clinic. Researchers from Memorial Sloan-Kettering Cancer Center, New York, now suggest that treating patients with a combination of the drugs might decrease the chance of the cancer returning, or at the very least increase the time before a relapse occurs

In the study, which appears online on August 16 in advance of publication in the September print issue of the Journal of Clinical Investigation, Charles Sawyers and colleagues show that 2 of 12 patients whose cancer had returned after treatment with dasatinib responded to retreatment with imatinib. Analysis of the BCR-ABL proteins from these patients revealed that their BCR-ABL had only the dasatinib-resistance mutation. By contrast, the BCR-ABL proteins of the other patients had either a single mutation that rendered the protein resistant to both dasatinib and imatinib or had two mutations, one rendering the protein resistant to imatinib and one rendering the protein resistant to dasatinib. A third drug that can target dasatinib- and imatinib-resitant BCR-ABL is currently in clinical trials. The authors therefore suggest that rather than treating CML patients with the drugs that target BCR-ABL sequentially, they should receive all the drugs when they are first diagnosed with the disease so that the emergence of the drug-resistant forms of BCR-ABL might be prevented, or at least delayed.


'/>"/>
Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Vitamin B12 can help in detecting cancers
6. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Want skin cancer? Please have a cigarette
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... The StayWell Company and VUCA ... manage patient health risks, foster behavior change and improve health literacy among patients. VUCA ... present a demonstration of its video capability at StayWell booth 3443 during HiMSS. ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... range of emergency dental care at his office, Antoine Dental Center. Emergency dentistry ... dental emergencies, they are at risk for serious complications and often experience severe ...
(Date:2/19/2017)... Carolina (PRWEB) , ... February 19, 2017 , ... The ... evening undergraduate nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged ... initial operations of the nursing department in early 2016. After a nation-wide search, she ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion ... Film Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... Users can pick and choose from hand-crafted trend-setting designs with smooth animations that ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... , Feb. 20, 2017  This report analyzes the worldwide markets ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Read the full report: http://www.reportlinker.com/p04707127-summary/view-report.html ... through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017 /PRNewswire/ ... are helping physicians diagnose and treat patients with ... will provide wireless connectivity for ZywiePro, Zywie,s cardiac ... AT&T Control Center . AT&T ... accessible monitoring for those with the disease. The ...
(Date:2/20/2017)... 20, 2017  There has been a paradigm shift ... across sub-Saharan Africa, which in turn is driving the ... more Western lifestyle diseases such as cardiovascular disease (CVD), ... and parasitic illness, will present the pharmaceutical industry in ... of $40.8 billion in 2019. "An increase ...
Breaking Medicine Technology: